During the COVID-19 pandemic, medical imaging proved indispensable for diagnosing and monitoring lung involvement. Among the available imaging modalities, computed tomography (CT) scanners became a cornerstone for assessing the severity and progression of lung manifestations caused by SARS-CoV-2. While reverse transcriptase polymerase chain reaction (RT-PCR) testing remained the gold standard for diagnosis, CT imaging offered rapid, detailed cross-sectional views of the pulmonary parenchyma, enabling clinicians to detect early changes, guide triage decisions, and track disease evolution. This article delves into the multifaceted role of CT scanners in detecting, characterizing, and monitoring COVID-19 lung manifestations, highlighting their clinical utility, typical imaging patterns, and limitations.

Understanding CT Scans and Their Role in Lung Assessment

Computed tomography utilizes X-ray projections acquired from multiple angles to generate high-resolution axial images. Modern multidetector CT (MDCT) scanners acquire thin slices (≤1 mm) that allow reconstruction in coronal and sagittal planes, providing a three-dimensional understanding of lung anatomy. For COVID-19 assessment, non-contrast high-resolution CT (HRCT) of the chest is typically performed, as contrast agents are not routinely needed for evaluating parenchymal opacities. HRCT’s superior spatial resolution makes it exquisitely sensitive to subtle changes in lung attenuation, such as ground-glass opacities (GGO), which are among the earliest signs of COVID-19 pneumonia. The technique also allows quantification of disease extent through visual or automated scoring systems, such as the CT severity score, which correlates with clinical outcomes and has been used to stratify patients for intensive care.

CT Findings in COVID-19 Pneumonia

Classic Imaging Patterns

The typical CT findings in COVID-19 pneumonia have been well characterized through large series and meta-analyses. The most common pattern is bilateral, peripheral, and basal predominant GGO, often with a rounded morphology. Ground-glass opacities represent areas of increased attenuation that do not obscure underlying bronchovascular markings, reflecting partial airspace filling, interstitial thickening, or edema. As the disease progresses, GGO may coalesce into consolidation—areas of homogeneous opacification that obscure vessels and airways, indicating more complete airspace filling. Additional patterns include:

  • Crazy paving: GGO with superimposed interlobular and intralobular septal thickening, creating a mosaic pattern. This finding suggests more severe inflammation and has been associated with worse prognosis.
  • Reverse halo sign (atoll sign): A central GGO surrounded by a ring of consolidation, seen in organizing pneumonia phase.
  • Subpleural bands and reticulation: Linear opacities parallel to the pleura, often seen during the fibrotic phase.
  • Air bronchograms: Air-filled bronchi within consolidated lung, indicating patent airways surrounded by dense parenchyma.
  • Pleural thickening or effusion: Less common in COVID-19 but can occur in severe cases; pleural effusion is more typical of bacterial superinfection.

These patterns are not pathognomonic but when combined with clinical presentation and appropriate epidemiological context, they support a diagnosis of COVID-19 pneumonia. The RSNA expert consensus statement categorized CT findings into typical, indeterminate, and atypical for COVID-19, guiding reporting language and reducing inter-reader variability.

Distribution and Scoring

COVID-19 pneumonia typically demonstrates a peripheral and posterior predominant distribution, with the lower lobes most frequently affected. Bilateral involvement is reported in over 80% of cases. The extent of disease is often quantified using a CT severity score (CT-SS) that assigns a score from 0 to 5 for each of the five lung lobes based on the percentage of opacification (0: none, 1: <5%, 2: 5%–25%, 3: 25%–50%, 4: 50%–75%, 5: >75%). The total score (0–25) correlates well with clinical severity, oxygen requirements, and need for intubation. Serial scoring allows objective monitoring of disease progression or resolution.

Diagnostic Role of CT Compared to RT-PCR

Early in the pandemic, CT was proposed as a screening tool due to its high sensitivity (often reported >90% in symptomatic patients), especially in settings with limited PCR capacity. However, it has lower specificity, as many viral pneumonias (e.g., influenza, adenovirus) can mimic COVID-19 CT findings. A meta-analysis by Kim et al. (2020) in The Lancet Infectious Diseases found pooled sensitivity of 94% but specificity of 37% for CT diagnosis when using RT-PCR as reference. Thus, CT should not replace PCR but can serve as a complementary tool when PCR is negative but clinical suspicion remains high, or for rapid triage in emergency settings. The Fleischner Society published guidelines recommending CT in patients with moderate to severe symptoms, those with a changing clinical status, or those at high risk for complications.

Monitoring Disease Progression and Complications

Serial CT examinations are valuable for tracking the temporal evolution of COVID-19 lung disease. In the first week, GGO and small consolidations appear; during week 2–3, disease peaks with increased consolidation and crazy paving; after 3 weeks, resolution or fibrosis may occur. CT can identify complications such as:

  • Acute respiratory distress syndrome (ARDS): Diffuse bilateral opacities with air bronchograms and dense consolidation, often requiring mechanical ventilation.
  • Pulmonary thromboembolism: CT pulmonary angiography (CTPA) is indicated when there is clinical suspicion; COVID-19 is associated with a high incidence of thrombotic events.
  • Secondary bacterial or fungal pneumonia: Development of new cavities, pleural effusion, or air-fluid levels.
  • Fibrotic changes: Traction bronchiectasis, parenchymal bands, and honeycombing in patients who develop post-COVID fibrosis, especially in those with prolonged recovery.

Radiologists must be vigilant for these patterns, as they significantly alter management. A study in Scientific Reports demonstrated that CT scoring combined with inflammatory biomarkers improved prediction of disease progression in hospitalized patients.

Advantages and Limitations of CT in COVID-19

Advantages

  • High sensitivity: Identifies early parenchymal changes before symptoms appear or PCR turns positive.
  • Rapid acquisition: A chest CT can be obtained in under 30 seconds, minimizing patient breath-hold time and reducing motion artifact.
  • Quantifiable severity: Objective scoring allows longitudinal comparison and contributes to research and clinical trials.
  • Detection of alternative diagnoses: CT can identify other causes of respiratory symptoms (e.g., heart failure, pulmonary embolism, primary lung cancer) and guide appropriate therapy.

Limitations

  • Radiation exposure: Despite dose-reduction techniques, a chest CT typically delivers 1–5 mSv, which is not negligible, especially for younger patients or those requiring multiple scans.
  • Specificity concerns: Over-reliance on CT may lead to false positives, especially in regions with low prevalence of COVID-19.
  • Infection control: Patients must be transported to the CT suite, requiring strict decontamination protocols to prevent cross-infection.
  • Resource intensive: CT scanners require trained personnel and maintenance; during surges, availability may be limited.
  • Artificial intelligence (AI) assist: While AI algorithms have been developed to automate detection and severity scoring, their generalizability across populations and CT vendors remains under evaluation.

Future Perspectives: AI, Dual-Energy CT, and Long COVID

As the pandemic evolves, so does the imaging armamentarium. AI deep learning models trained on large datasets can now identify COVID-19 patterns on chest CT with high accuracy, potentially reducing radiologist workload and turnaround time. Dual-energy CT (DECT) provides additional information by differentiating materials, such as perfused versus non-perfused lung, which could help characterize pulmonary vascular involvement. Furthermore, as we recognize long COVID, CT plays a role in detecting persistent lung changes—such as fibrosis, mosaic attenuation due to air trapping, and vascular sequelae—in patients who remain symptomatic months after infection. The World Health Organization has highlighted the need for systematic follow-up of long COVID patients, and imaging is a key component.

Conclusion

Computed tomography has proven to be a critical tool in the fight against COVID-19, offering unmatched sensitivity for detecting lung involvement and providing a non-invasive method to monitor disease progression and guide clinical decisions. While limitations such as radiation exposure and specificity constraints require judicious use, CT remains invaluable, particularly for patients with moderate to severe disease or uncertain diagnoses. The integration of quantitative scoring, AI assistance, and advanced techniques like DECT will further enhance its role in both acute management and long-term follow-up. Ultimately, CT scanners have not only helped mitigate the immediate impact of the pandemic but have also enriched our understanding of viral pneumonia patterns and the long-term pulmonary consequences of SARS-CoV-2 infection.